Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1273161 | 0.95 | TGM2 (0.48) | TGM2TSHRNOD1SIRT2SIRT1 | |
| SCHEMBL30849132 | 0.85 | FOLH1 (0.50) | TGM2SLC6A5CASP1 | |
| SCHEMBL287193 | 0.85 | FOLH1 (0.50) | TGM2SLC6A5CASP1 | |
| SCHEMBL287192 | 0.85 | FOLH1 (0.50) | TGM2SLC6A5CASP1 | |
| SCHEMBL1273690 | 0.84 | TGM2 (0.47) | TGM2NOD1SIRT2SIRT1SLC6A5 | |
| SCHEMBL23705400 | 0.84 | TGM2 (0.52) | TGM2SIRT2SIRT1CASP1 | |
| SCHEMBL23705401 | 0.84 | TGM2 (0.52) | TGM2SIRT2SIRT1CASP1 | |
| SCHEMBL11001505 | 0.84 | CASP1 (0.45) | TGM2CASP1 | |
| SCHEMBL21315776 | 0.84 | FOLH1 (0.44) | TGM2SLC6A5CASP1 | |
| SCHEMBL7605714 | 0.84 | FOLH1 (0.44) | TGM2SLC6A5CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | TGM2 220/4885TSHR 2040/4885NOD1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.